Documentaries, videos and podcasts
May 19, 2021
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A - read this article along with other careers information, tips and advice on BioSpace
BioMarin Pharmaceutical Inc.
January 10, 2021
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of...
Be the first contributor by making edits